Four Stocks Seeing Record Volume (ALXA, BORN, TAL, CWF)
While the volume of the overall market has become a less reliable indicator of future movement in an index, volume on individual names continues to allow for trading setups with defined risk levels and the potential for snap backs (mean reversion), which is just what institutional stock traders search for.
Here are four names that are seeing very high volume levels, higher than the past 52-weeks…
1. Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. The stock has traded 13,867,971 times during the session, which is 7.68x the 10-day average and a new 52-week high.
2. China New Borun Corporation (NYSE: BORN) is a producer and distributor of corn-based edible alcohol in the People's Republic of China based on tons of edible alcohol produced. The company's edible alcohol products are primarily sold as an ingredient to producers of baijiu, who further blend the company's products into finished products sold under various brand names throughout China. The stock has traded 3,627,769 times during the session, which is 2.61x the 10-day average and a new 52-week high.
3. TAL International Group, Inc. (NYSE: TAL) is a lessor of intermodal containers and chassis. The Company operates its business in one industry, intermodal transportation equipment, and has two business segments: Equipment leasing and Equipment trading. The stock has traded 705,043 times during the session, which is 3.35x the 10-day average and a new 52-week high.
4. Chartwell Dividend and Income Fund, Inc. (NYSE: CWF) is a closed-end management investment company. The fund's primary investment objective is to seek high current income. Capital appreciation is a secondary objective. The fund has traded 191,564 times during the session, which is 3.30x the 10-day average and a new 52-week high.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.